My laboratory explores the molecular basis for neurotransmitter transporter structure, function and regulation. We use chimera, site-directed mutagenesis and site-specific chemical modification strategies to explore the topology and quaternary structure of biogenic amine transporters. We are evaluating what molecules control the proper localization and activity of transporter proteins using genetic (C.elegans), and molecular biologic methods. We are also evaluating whether human transporter polymorphisms impact the biosynthesis, trafficking and function of transporters and confer increased risk for autonomic, neurologic and mental disorders.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Acute blockade of the Caenorhabditis elegans dopamine transporter DAT-1 by the mammalian norepinephrine transporter inhibitor nisoxetine reveals the influence of genetic modifications of dopamine signaling in vivo. Bermingham DP, Hardaway JA, Snarrenberg CL, Robinson SB, Folkes OM, Salimando GJ, Jinnah H, Blakely RD (2016) Neurochem Int : 122-8
    › Primary publication · 26850478 (PubMed) · PMC4969213 (PubMed Central)
  2. Physical Interactions and Functional Relationships of Neuroligin 2 and Midbrain Serotonin Transporters. Ye R, Quinlan MA, Iwamoto H, Wu HH, Green NH, Jetter CS, McMahon DG, Veestra-VanderWeele J, Levitt P, Blakely RD (2015) Front Synaptic Neurosci : 20
    › Primary publication · 26793096 (PubMed) · PMC4707279 (PubMed Central)
  3. A requirement of serotonergic p38α mitogen-activated protein kinase for peripheral immune system activation of CNS serotonin uptake and serotonin-linked behaviors. Baganz NL, Lindler KM, Zhu CB, Smith JT, Robson MJ, Iwamoto H, Deneris ES, Hewlett WA, Blakely RD (2015) Transl Psychiatry : e671
    › Primary publication · 26529424 (PubMed) · PMC5068761 (PubMed Central)
  4. Glial Expression of the Caenorhabditis elegans Gene swip-10 Supports Glutamate Dependent Control of Extrasynaptic Dopamine Signaling. Hardaway JA, Sturgeon SM, Snarrenberg CL, Li Z, Xu XZ, Bermingham DP, Odiase P, Spencer WC, Miller DM, Carvelli L, Hardie SL, Blakely RD (2015) J Neurosci 35(25): 9409-23
    › Primary publication · 26109664 (PubMed) · PMC4478255 (PubMed Central)
  5. Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise. Kohli U, Diedrich A, Kannankeril PJ, Muszkat M, Sofowora GG, Hahn MK, English BA, Blakely RD, Stein CM, Kurnik D (2015) Physiol Genomics 47(9): 400-6
    › Primary publication · 26058836 (PubMed) · PMC4556937 (PubMed Central)
  6. Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter. Bollinger SR, Engers DW, Ennis EA, Wright J, Locuson CW, Lindsley CW, Blakely RD, Hopkins CR (2015) Bioorg Med Chem Lett 25(8): 1757-1760
    › Primary publication · 25801932 (PubMed) · PMC4385452 (PubMed Central)
  7. Single-quantum-dot tracking reveals altered membrane dynamics of an attention-deficit/hyperactivity-disorder-derived dopamine transporter coding variant. Kovtun O, Sakrikar D, Tomlinson ID, Chang JC, Arzeta-Ferrer X, Blakely RD, Rosenthal SJ (2015) ACS Chem Neurosci 6(4): 526-34
    › Primary publication · 25747272 (PubMed) · PMC5530757 (PubMed Central)
  8. 3D visualization of the regional differences. Ellegood J, Anagnostou E, Babineau BA, Crawley JN, Lin L, Genestine M, DiCicco-Bloom E, Lai JK, Foster JA, Peñagarikano O, Geschwind DH, Pacey LK, Hampson DR, Laliberté CL, Mills AA, Tam E, Osborne LR, Kouser M, Espinosa-Becerra F, Xuan Z, Powell CM, Raznahan A, Robins DM, Nakai N, Nakatani J, Takumi T, van Eede MC, Kerr TM, Muller C, Blakely RD, Veenstra-VanderWeele J, Henkelman RM, Lerch JP (2015) Mol Psychiatry 20(1): 1
    › Primary publication · 25648202 (PubMed) · PMC5131793 (PubMed Central)
  9. Disruption of Transient Serotonin Accumulation by Non-Serotonin-Producing Neurons Impairs Cortical Map Development. Chen X, Ye R, Gargus JJ, Blakely RD, Dobrenis K, Sze JY (2015) Cell Rep 10(3): 346-358
    › Primary publication · 25600870 (PubMed) · PMC4824665 (PubMed Central)
  10. Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporter. Ennis EA, Wright J, Retzlaff CL, McManus OB, Lin Z, Huang X, Wu M, Li M, Daniels JS, Lindsley CW, Hopkins CR, Blakely RD (2015) ACS Chem Neurosci 6(3): 417-27
    › Primary publication · 25560927 (PubMed) · PMC4367188 (PubMed Central)
  11. Cholinergic capacity mediates prefrontal engagement during challenges to attention: evidence from imaging genetics. Berry AS, Blakely RD, Sarter M, Lustig C (2015) Neuroimage : 386-95
    › Primary publication · 25536497 (PubMed) · PMC4469545 (PubMed Central)
  12. The rare DAT coding variant Val559 perturbs DA neuron function, changes behavior, and alters in vivo responses to psychostimulants. Mergy MA, Gowrishankar R, Gresch PJ, Gantz SC, Williams J, Davis GL, Wheeler CA, Stanwood GD, Hahn MK, Blakely RD (2014) Proc Natl Acad Sci U S A 111(44): E4779-88
    › Primary publication · 25331903 (PubMed) · PMC4226116 (PubMed Central)
  13. SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. Bowton E, Saunders C, Reddy IA, Campbell NG, Hamilton PJ, Henry LK, Coon H, Sakrikar D, Veenstra-VanderWeele JM, Blakely RD, Sutcliffe J, Matthies HJ, Erreger K, Galli A (2014) Transl Psychiatry : e464
    › Primary publication · 25313507 (PubMed) · PMC4350523 (PubMed Central)
  14. Clustering autism: using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. Ellegood J, Anagnostou E, Babineau BA, Crawley JN, Lin L, Genestine M, DiCicco-Bloom E, Lai JK, Foster JA, Peñagarikano O, Geschwind DH, Pacey LK, Hampson DR, Laliberté CL, Mills AA, Tam E, Osborne LR, Kouser M, Espinosa-Becerra F, Xuan Z, Powell CM, Raznahan A, Robins DM, Nakai N, Nakatani J, Takumi T, van Eede MC, Kerr TM, Muller C, Blakely RD, Veenstra-VanderWeele J, Henkelman RM, Lerch JP (2015) Mol Psychiatry 20(1): 118-25
    › Primary publication · 25199916 (PubMed) · PMC4426202 (PubMed Central)
  15. Cocaine modulates mammalian circadian clock timing by decreasing serotonin transport in the SCN. Prosser RA, Stowie A, Amicarelli M, Nackenoff AG, Blakely RD, Glass JD (2014) Neuroscience : 184-93
    › Primary publication · 24950119 (PubMed) · PMC4122660 (PubMed Central)
  16. An open-source analytical platform for analysis of C. elegans swimming-induced paralysis. Hardaway JA, Wang J, Fleming PA, Fleming KA, Whitaker SM, Nackenoff A, Snarrenberg CL, Hardie SL, Zhang B, Blakely RD (2014) J Neurosci Methods : 58-62
    › Primary publication · 24792527 (PubMed) · PMC4179448 (PubMed Central)
  17. The brain in flux: genetic, physiologic, and therapeutic perspectives on transporters in the CNS. Blakely RD, Ortega A, Robinson MB (2014) Neurochem Int : 1-3
    › Primary publication · 24751395 (PubMed)
  18. Disposed to distraction: genetic variation in the cholinergic system influences distractibility but not time-on-task effects. Berry AS, Demeter E, Sabhapathy S, English BA, Blakely RD, Sarter M, Lustig C (2014) J Cogn Neurosci 26(9): 1981-91
    › Primary publication · 24666128 (PubMed) · PMC4445375 (PubMed Central)
  19. Dopamine denervation of the prefrontal cortex increases expression of the astrocytic glutamate transporter GLT-1. Vollbrecht PJ, Simmler LD, Blakely RD, Deutch AY (2014) J Neurochem 130(1): 109-14
    › Primary publication · 24611756 (PubMed) · PMC4065617 (PubMed Central)
  20. Quantitative trait loci mapping and gene network analysis implicate protocadherin-15 as a determinant of brain serotonin transporter expression. Ye R, Carneiro AM, Han Q, Airey D, Sanders-Bush E, Zhang B, Lu L, Williams R, Blakely RD (2014) Genes Brain Behav 13(3): 261-75
    › Primary publication · 24405699 (PubMed) · PMC4436591 (PubMed Central)
  21. The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Rudnick G, Krämer R, Blakely RD, Murphy DL, Verrey F (2014) Pflugers Arch 466(1): 25-42
    › Primary publication · 24337881 (PubMed) · PMC3930102 (PubMed Central)
  22. Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder. Mergy MA, Gowrishankar R, Davis GL, Jessen TN, Wright J, Stanwood GD, Hahn MK, Blakely RD (2014) Neurochem Int : 56-70
    › Primary publication · 24332984 (PubMed) · PMC4177817 (PubMed Central)
  23. Transgenic overexpression of the presynaptic choline transporter elevates acetylcholine levels and augments motor endurance. Holmstrand EC, Lund D, Cherian AK, Wright J, Martin RF, Ennis EA, Stanwood GD, Sarter M, Blakely RD (2014) Neurochem Int : 217-28
    › Primary publication · 24274995 (PubMed) · PMC4104494 (PubMed Central)
  24. Good riddance to dopamine: roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders. Gowrishankar R, Hahn MK, Blakely RD (2014) Neurochem Int : 42-8
    › Primary publication · 24231471 (PubMed)
  25. Evaluation of heritable determinants of blood and brain serotonin homeostasis using recombinant inbred mice. Ye R, Carneiro AM, Airey D, Sanders-Bush E, Williams RW, Lu L, Wang J, Zhang B, Blakely RD (2014) Genes Brain Behav 13(3): 247-60
    › Primary publication · 24102824 (PubMed) · PMC3979832 (PubMed Central)
  26. Genetic background modulates phenotypes of serotonin transporter Ala56 knock-in mice. Kerr TM, Muller CL, Miah M, Jetter CS, Pfeiffer R, Shah C, Baganz N, Anderson GM, Crawley JN, Sutcliffe JS, Blakely RD, Veenstra-Vanderweele J (2013) Mol Autism 4(1): 35
    › Primary publication · 24083388 (PubMed) · PMC3851031 (PubMed Central)
  27. Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits. Paolone G, Mallory CS, Cherian AK, Miller TR, Blakely RD, Sarter M (2013) Neuropharmacology : 274-85
    › Primary publication · 23958450 (PubMed) · PMC3865115 (PubMed Central)
  28. Rare coding variants of the adenosine A3 receptor are increased in autism: on the trail of the serotonin transporter regulome. Campbell NG, Zhu CB, Lindler KM, Yaspan BL, Kistner-Griffin E, NIH ARRA Consortium, Hewlett WA, Tate CG, Blakely RD, Sutcliffe JS (2013) Mol Autism 4(1): 28
    › Primary publication · 23953133 (PubMed) · PMC3882891 (PubMed Central)
  29. Choline transporter hemizygosity results in diminished basal extracellular dopamine levels in nucleus accumbens and blunts dopamine elevations following cocaine or nicotine. Dong Y, Dani JA, Blakely RD (2013) Biochem Pharmacol 86(8): 1084-8
    › Primary publication · 23939187 (PubMed) · PMC4413453 (PubMed Central)
  30. The presynaptic choline transporter imposes limits on sustained cortical acetylcholine release and attention. Parikh V, St Peters M, Blakely RD, Sarter M (2013) J Neurosci 33(6): 2326-37
    › Primary publication · 23392663 (PubMed) · PMC3711270 (PubMed Central)
  31. A dialogue between the immune system and brain, spoken in the language of serotonin. Baganz NL, Blakely RD (2013) ACS Chem Neurosci 4(1): 48-63
    › Primary publication · 23336044 (PubMed) · PMC3547518 (PubMed Central)
  32. Phosphorylation of dopamine transporter serine 7 modulates cocaine analog binding. Moritz AE, Foster JD, Gorentla BK, Mazei-Robison MS, Yang JW, Sitte HH, Blakely RD, Vaughan RA (2013) J Biol Chem 288(1): 20-32
    › Primary publication · 23161550 (PubMed) · PMC3537014 (PubMed Central)
  33. Defective presynaptic choline transport underlies hereditary motor neuropathy. Barwick KE, Wright J, Al-Turki S, McEntagart MM, Nair A, Chioza B, Al-Memar A, Modarres H, Reilly MM, Dick KJ, Ruggiero AM, Blakely RD, Hurles ME, Crosby AH (2012) Am J Hum Genet 91(6): 1103-7
    › Primary publication · 23141292 (PubMed) · PMC3516609 (PubMed Central)
  34. Nonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake. Ruggiero AM, Wright J, Ferguson SM, Lewis M, Emerson KS, Iwamoto H, Ivy MT, Holmstrand EC, Ennis EA, Weaver CD, Blakely RD (2012) ACS Chem Neurosci 3(10): 767-81
    › Primary publication · 23077721 (PubMed) · PMC3474274 (PubMed Central)
  35. Forward genetic analysis to identify determinants of dopamine signaling in Caenorhabditis elegans using swimming-induced paralysis. Hardaway JA, Hardie SL, Whitaker SM, Baas SR, Zhang B, Bermingham DP, Lichtenstein AJ, Blakely RD (2012) G3 (Bethesda) 2(8): 961-75
    › Primary publication · 22908044 (PubMed) · PMC3411251 (PubMed Central)
  36. Labeling of neuronal receptors and transporters with quantum dots. Chang JC, Kovtun O, Blakely RD, Rosenthal SJ (2012) Wiley Interdiscip Rev Nanomed Nanobiotechnol 4(6): 605-19
    › Primary publication · 22887823 (PubMed) · PMC3753009 (PubMed Central)
  37. Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice. Zurkovsky L, Bychkov E, Tsakem EL, Siedlecki C, Blakely RD, Gurevich EV (2013) Dis Model Mech 6(1): 171-83
    › Primary publication · 22864020 (PubMed) · PMC3529349 (PubMed Central)
  38. Visualization of the cocaine-sensitive dopamine transporter with ligand-conjugated quantum dots. Kovtun O, Tomlinson ID, Sakrikar DS, Chang JC, Blakely RD, Rosenthal SJ (2011) ACS Chem Neurosci 2(7): 370-8
    › Primary publication · 22816024 (PubMed) · PMC3369746 (PubMed Central)
  39. Y95 and E444 interaction required for high-affinity S-citalopram binding in the human serotonin transporter. Combs S, Kaufmann K, Field JR, Blakely RD, Meiler J (2011) ACS Chem Neurosci 2(2): 75-81
    › Primary publication · 22778858 (PubMed) · PMC3369724 (PubMed Central)
  40. Single molecule analysis of serotonin transporter regulation using antagonist-conjugated quantum dots reveals restricted, p38 MAPK-dependent mobilization underlying uptake activation. Chang JC, Tomlinson ID, Warnement MR, Ustione A, Carneiro AM, Piston DW, Blakely RD, Rosenthal SJ (2012) J Neurosci 32(26): 8919-29
    › Primary publication · 22745492 (PubMed) · PMC3426861 (PubMed Central)
  41. Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation. Sakrikar D, Mazei-Robison MS, Mergy MA, Richtand NW, Han Q, Hamilton PJ, Bowton E, Galli A, Veenstra-Vanderweele J, Gill M, Blakely RD (2012) J Neurosci 32(16): 5385-97
    › Primary publication · 22514303 (PubMed) · PMC3342037 (PubMed Central)
  42. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR, Cohen J, Mannangatti P, Jessen T, Thompson BJ, Ye R, Kerr TM, Carneiro AM, Crawley JN, Sanders-Bush E, McMahon DG, Ramamoorthy S, Daws LC, Sutcliffe JS, Blakely RD (2012) Proc Natl Acad Sci U S A 109(14): 5469-74
    › Primary publication · 22431635 (PubMed) · PMC3325657 (PubMed Central)
  43. The SSRI citalopram affects fetal thalamic axon responsiveness to netrin-1 in vitro independently of SERT antagonism. Bonnin A, Zhang L, Blakely RD, Levitt P (2012) Neuropsychopharmacology 37(8): 1879-84
    › Primary publication · 22414815 (PubMed) · PMC3376320 (PubMed Central)
  44. Vesicular and plasma membrane transporters for neurotransmitters. Blakely RD, Edwards RH (2012) Cold Spring Harb Perspect Biol 4(2)
    › Primary publication · 22199021 (PubMed) · PMC3281572 (PubMed Central)
  45. A fluorescence displacement assay for antidepressant drug discovery based on ligand-conjugated quantum dots. Chang JC, Tomlinson ID, Warnement MR, Iwamoto H, DeFelice LJ, Blakely RD, Rosenthal SJ (2011) J Am Chem Soc 133(44): 17528-31
    › Primary publication · 21970724 (PubMed) · PMC3235909 (PubMed Central)
  46. Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments. Veenstra-VanderWeele J, Blakely RD (2012) Neuropsychopharmacology 37(1): 196-212
    › Primary publication · 21937981 (PubMed) · PMC3238072 (PubMed Central)
  47. Natural and engineered coding variation in antidepressant-sensitive serotonin transporters. Ye R, Blakely RD (2011) Neuroscience : 28-36
    › Primary publication · 21893166 (PubMed) · PMC3850749 (PubMed Central)
  48. A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport. Henry LK, Iwamoto H, Field JR, Kaufmann K, Dawson ES, Jacobs MT, Adams C, Felts B, Zdravkovic I, Armstrong V, Combs S, Solis E, Rudnick G, Noskov SY, DeFelice LJ, Meiler J, Blakely RD (2011) J Biol Chem 286(35): 30823-30836
    › Primary publication · 21730057 (PubMed) · PMC3162443 (PubMed Central)
  49. Colocalization and regulated physical association of presynaptic serotonin transporters with A₃ adenosine receptors. Zhu CB, Lindler KM, Campbell NG, Sutcliffe JS, Hewlett WA, Blakely RD (2011) Mol Pharmacol 80(3): 458-65
    › Primary publication · 21705486 (PubMed) · PMC3164334 (PubMed Central)
  50. Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene. Gilbert J, Haman KL, Dietrich MS, Blakely RD, Shelton RC, Murphy BA (2012) Head Neck 34(3): 359-64
    › Primary publication · 21604315 (PubMed)
  51. Choline transporter gene variation is associated with attention-deficit hyperactivity disorder. English BA, Hahn MK, Gizer IR, Mazei-Robison M, Steele A, Kurnik DM, Stein MA, Waldman ID, Blakely RD (2009) J Neurodev Disord 1(4): 252-63
    › Primary publication · 21547719 (PubMed) · PMC3164006 (PubMed Central)
  52. Genetic indeterminism, the 5-HTTLPR, and the paths forward in neuropsychiatric genetics. Blakely RD, Veenstra-VanderWeele J (2011) Arch Gen Psychiatry 68(5): 457-8
    › Primary publication · 21536974 (PubMed) · PMC3686479 (PubMed Central)
  53. A transient placental source of serotonin for the fetal forebrain. Bonnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC, Blakely RD, Deneris ES, Levitt P (2011) Nature 472(7343): 347-50
    › Primary publication · 21512572 (PubMed) · PMC3084180 (PubMed Central)
  54. Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans. Kohli U, Hahn MK, English BA, Sofowora GG, Muszkat M, Li C, Blakely RD, Stein CM, Kurnik D (2011) Pharmacogenet Genomics 21(4): 171-8
    › Primary publication · 21412203 (PubMed) · PMC3065933 (PubMed Central)
  55. Effect of chronic mild stress on serotonergic markers in the skin and brain of the NC/Nga atopic-like mouse strain. Rasul A, El-Nour H, Blakely RD, Lonne-Rahm SB, Forsberg J, Johansson B, Theodorsson E, Nordlind K (2011) Arch Dermatol Res 303(9): 625-33
    › Primary publication · 21400247 (PubMed)
  56. Biotin tethered homotryptamine derivatives: high affinity probes of the human serotonin transporter (hSERT). Tomlinson ID, Iwamoto H, Blakely RD, Rosenthal SJ (2011) Bioorg Med Chem Lett 21(6): 1678-82
    › Primary publication · 21334895 (PubMed) · PMC3070488 (PubMed Central)
  57. Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter. Thompson BJ, Jessen T, Henry LK, Field JR, Gamble KL, Gresch PJ, Carneiro AM, Horton RE, Chisnell PJ, Belova Y, McMahon DG, Daws LC, Blakely RD (2011) Proc Natl Acad Sci U S A 108(9): 3785-90
    › Primary publication · 21282638 (PubMed) · PMC3048100 (PubMed Central)
  58. Chronic desipramine treatment alters tyrosine hydroxylase but not norepinephrine transporter immunoreactivity in norepinephrine axons in the rat prefrontal cortex. Erickson SL, Gandhi AR, Asafu-Adjei JK, Sampson AR, Miner L, Blakely RD, Sesack SR (2011) Int J Neuropsychopharmacol 14(9): 1219-32
    › Primary publication · 21208501 (PubMed) · PMC3117082 (PubMed Central)
  59. Dependence of serotonergic and other nonadrenergic enteric neurons on norepinephrine transporter expression. Li Z, Caron MG, Blakely RD, Margolis KG, Gershon MD (2010) J Neurosci 30(49): 16730-40
    › Primary publication · 21148012 (PubMed) · PMC3066093 (PubMed Central)
  60. Motor neuron-specific overexpression of the presynaptic choline transporter: impact on motor endurance and evoked muscle activity. Lund D, Ruggiero AM, Ferguson SM, Wright J, English BA, Reisz PA, Whitaker SM, Peltier AC, Blakely RD (2010) Neuroscience 171(4): 1041-53
    › Primary publication · 20888396 (PubMed) · PMC2992794 (PubMed Central)
  61. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA (2010) Neuropsychopharmacology 35(13): 2510-20
    › Primary publication · 20827273 (PubMed) · PMC3055584 (PubMed Central)
  62. Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter. English BA, Appalsamy M, Diedrich A, Ruggiero AM, Lund D, Wright J, Keller NR, Louderback KM, Robertson D, Blakely RD (2010) Am J Physiol Heart Circ Physiol 299(3): H799-810
    › Primary publication · 20601463 (PubMed) · PMC2944482 (PubMed Central)
  63. Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking. Matthies HJ, Moore JL, Saunders C, Matthies DS, Lapierre LA, Goldenring JR, Blakely RD, Galli A (2010) J Neurosci 30(23): 7863-77
    › Primary publication · 20534835 (PubMed) · PMC2935280 (PubMed Central)
  64. Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N, Jessen T, Colbran RJ, Caron MG, Javitch JA, Blakely RD, Galli A (2010) J Neurosci 30(17): 6048-57
    › Primary publication · 20427663 (PubMed) · PMC2881830 (PubMed Central)
  65. Ultrastructural localization of high-affinity choline transporter in the rat anteroventral thalamus and ventral tegmental area: differences in axon morphology and transporter distribution. Holmstrand EC, Asafu-Adjei J, Sampson AR, Blakely RD, Sesack SR (2010) J Comp Neurol 518(11): 1908-24
    › Primary publication · 20394050 (PubMed) · PMC3105597 (PubMed Central)
  66. Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylene dioxymethamphetamine. Field JR, Henry LK, Blakely RD (2010) J Biol Chem 285(15): 11270-80
    › Primary publication · 20159976 (PubMed) · PMC2857005 (PubMed Central)
  67. Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse. Veenstra-Vanderweele J, Jessen TN, Thompson BJ, Carter M, Prasad HC, Steiner JA, Sutcliffe JS, Blakely RD (2009) J Neurodev Disord 1(2): 158-71
    › Primary publication · 19960097 (PubMed) · PMC2786076 (PubMed Central)
  68. Targeting the human serotonin transporter (hSERT) with quantum dots. Tomlinson ID, Chang J, Iwamoto H, De Felice LJ, Blakely RD, Rosenthal SJ (2008) Proc SPIE Int Soc Opt Eng 6866(68660X): nihpa155701
    › Primary publication · 19936040 (PubMed) · PMC2779040 (PubMed Central)
  69. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, Paolocci N (2010) Circ Res 106(1): 193-202
    › Primary publication · 19910579 (PubMed) · PMC2804073 (PubMed Central)
  70. cGMP-dependent protein kinase Ialpha associates with the antidepressant-sensitive serotonin transporter and dictates rapid modulation of serotonin uptake. Steiner JA, Carneiro AM, Wright J, Matthies HJ, Prasad HC, Nicki CK, Dostmann WR, Buchanan CC, Corbin JD, Francis SH, Blakely RD (2009) Mol Brain : 26
    › Primary publication · 19656393 (PubMed) · PMC2731736 (PubMed Central)
  71. Monoamine oxidase a promoter gene associated with problem behavior in adults with intellectual/developmental disabilities. May ME, Srour A, Hedges LK, Lightfoot DA, Phillips JA, Blakely RD, Kennedy CH (2009) Am J Intellect Dev Disabil 114(4): 269-73
    › Primary publication · 19642709 (PubMed)
  72. Subcellular localization of the antidepressant-sensitive norepinephrine transporter. Matthies HJ, Han Q, Shields A, Wright J, Moore JL, Winder DG, Galli A, Blakely RD (2009) BMC Neurosci : 65
    › Primary publication · 19545450 (PubMed) · PMC2716352 (PubMed Central)
  73. Serotonin rising. Anderson GM, Cook EH, Blakely RD (2009) N Engl J Med 360(24): 2580; author reply 2581-2
    › Primary publication · 19516042 (PubMed)
  74. Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes. Carneiro AM, Airey DC, Thompson B, Zhu CB, Lu L, Chesler EJ, Erikson KM, Blakely RD (2009) Proc Natl Acad Sci U S A 106(6): 2047-52
    › Primary publication · 19179283 (PubMed) · PMC2632716 (PubMed Central)
  75. Hereditary spastic paraplegia-associated mutations in the NIPA1 gene and its Caenorhabditis elegans homolog trigger neural degeneration in vitro and in vivo through a gain-of-function mechanism. Zhao J, Matthies DS, Botzolakis EJ, Macdonald RL, Blakely RD, Hedera P (2008) J Neurosci 28(51): 13938-51
    › Primary publication · 19091982 (PubMed) · PMC2660329 (PubMed Central)
  76. Psychiatric profile and attention deficits in postural tachycardia syndrome. Raj V, Haman KL, Raj SR, Byrne D, Blakely RD, Biaggioni I, Robertson D, Shelton RC (2009) J Neurol Neurosurg Psychiatry 80(3): 339-44
    › Primary publication · 18977825 (PubMed) · PMC2758320 (PubMed Central)
  77. Enhanced activity of human serotonin transporter variants associated with autism. Prasad HC, Steiner JA, Sutcliffe JS, Blakely RD (2009) Philos Trans R Soc Lond B Biol Sci 364(1514): 163-73
    › Primary publication · 18957375 (PubMed) · PMC2674096 (PubMed Central)
  78. Dopamine transporter/syntaxin 1A interactions regulate transporter channel activity and dopaminergic synaptic transmission. Carvelli L, Blakely RD, DeFelice LJ (2008) Proc Natl Acad Sci U S A 105(37): 14192-7
    › Primary publication · 18768815 (PubMed) · PMC2528871 (PubMed Central)
  79. Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies. Kaufmann KW, Dawson ES, Henry LK, Field JR, Blakely RD, Meiler J (2009) Proteins 74(3): 630-42
    › Primary publication · 18704946 (PubMed) · PMC2782712 (PubMed Central)
  80. Cholinergic neurons of mouse intrinsic cardiac ganglia contain noradrenergic enzymes, norepinephrine transporters, and the neurotrophin receptors tropomyosin-related kinase A and p75. Hoard JL, Hoover DB, Mabe AM, Blakely RD, Feng N, Paolocci N (2008) Neuroscience 156(1): 129-42
    › Primary publication · 18674600 (PubMed) · PMC2640831 (PubMed Central)
  81. Anomalous dopamine release associated with a human dopamine transporter coding variant. Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH, Galli A, Blakely RD (2008) J Neurosci 28(28): 7040-6
    › Primary publication · 18614672 (PubMed) · PMC2573963 (PubMed Central)
  82. Functional gene variation in the human norepinephrine transporter: association with attention deficit hyperactivity disorder. Kim CH, Waldman ID, Blakely RD, Kim KS (2008) Ann N Y Acad Sci : 256-60
    › Primary publication · 18591486 (PubMed)
  83. Aberrant trafficking of the high-affinity choline transporter in AP-3-deficient mice. Misawa H, Fujigaya H, Nishimura T, Moriwaki Y, Okuda T, Kawashima K, Nakata K, Ruggiero AM, Blakely RD, Nakatsu F, Ohno H (2008) Eur J Neurosci 27(12): 3109-17
    › Primary publication · 18554297 (PubMed)
  84. Going with the flow: trafficking-dependent and -independent regulation of serotonin transport. Steiner JA, Carneiro AM, Blakely RD (2008) Traffic 9(9): 1393-402
    › Primary publication · 18445122 (PubMed) · PMC2773847 (PubMed Central)
  85. Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. Carneiro AM, Cook EH, Murphy DL, Blakely RD (2008) J Clin Invest 118(4): 1544-52
    › Primary publication · 18317590 (PubMed) · PMC2260909 (PubMed Central)
  86. Quantum dot ex vivo labeling of neuromuscular synapses. Orndorff RL, Warnement MR, Mason JN, Blakely RD, Rosenthal SJ (2008) Nano Lett 8(3): 780-5
    › Primary publication · 18237149 (PubMed)
  87. Bound to be different: neurotransmitter transporters meet their bacterial cousins. Henry LK, Meiler J, Blakely RD (2007) Mol Interv 7(6): 306-9
    › Primary publication · 18199851 (PubMed)
  88. Distinctions between dopamine transporter antagonists could be just around the bend. Henry LK, Blakely RD (2008) Mol Pharmacol 73(3): 616-8
    › Primary publication · 18156312 (PubMed)
  89. Vigorous motor activity in Caenorhabditis elegans requires efficient clearance of dopamine mediated by synaptic localization of the dopamine transporter DAT-1. McDonald PW, Hardie SL, Jessen TN, Carvelli L, Matthies DS, Blakely RD (2007) J Neurosci 27(51): 14216-27
    › Primary publication · 18094261 (PubMed) · PMC6673513 (PubMed Central)
  90. Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression. Hahn MK, Blackford JU, Haman K, Mazei-Robison M, English BA, Prasad HC, Steele A, Hazelwood L, Fentress HM, Myers R, Blakely RD, Sanders-Bush E, Shelton R (2008) Genes Brain Behav 7(4): 487-95
    › Primary publication · 18081710 (PubMed) · PMC2670227 (PubMed Central)
  91. Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, France CP, Gore JC, Daws LC, Avison MJ, Galli A (2007) PLoS Biol 5(10): e274
    › Primary publication · 17941718 (PubMed) · PMC2020502 (PubMed Central)
  92. Synthesis and characterization of a pegylated derivative of 3-(1,2,3,6-tetrahydro-pyridin-4yl)-1H-indole (IDT199): a high affinity SERT ligand for conjugation to quantum dots. Tomlinson ID, Warnerment MR, Mason JN, Vergne MJ, Hercules DM, Blakely RD, Rosenthal SJ (2007) Bioorg Med Chem Lett 17(20): 5656-60
    › Primary publication · 17766114 (PubMed)
  93. Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD (2007) J Pharmacol Exp Ther 323(2): 720-9
    › Primary publication · 17673606 (PubMed)
  94. Tegaserod inhibits the serotonin transporter SERT. Ismair MG, Kullak-Ublick GA, Blakely RD, Fried M, Vavricka SR (2007) Digestion 75(2-3): 90-5
    › Primary publication · 17510552 (PubMed)
  95. Rapid stimulation of presynaptic serotonin transport by A(3) adenosine receptors. Zhu CB, Steiner JA, Munn JL, Daws LC, Hewlett WA, Blakely RD (2007) J Pharmacol Exp Ther 322(1): 332-40
    › Primary publication · 17460150 (PubMed)
  96. All aglow about presynaptic receptor regulation of neurotransmitter transporters. Blakely RD, DeFelice LJ (2007) Mol Pharmacol 71(5): 1206-8
    › Primary publication · 17329498 (PubMed)
  97. An automated fluorescence-based method for continuous assay of PP2A activity. Wegner AM, McConnell JL, Blakely RD, Wadzinski BE (2007) Methods Mol Biol : 61-9
    › Primary publication · 17200554 (PubMed)
  98. Calcium-dependent interactions of the human norepinephrine transporter with syntaxin 1A. Sung U, Blakely RD (2007) Mol Cell Neurosci 34(2): 251-60
    › Primary publication · 17188889 (PubMed) · PMC1847414 (PubMed Central)
  99. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Kim CH, Hahn MK, Joung Y, Anderson SL, Steele AH, Mazei-Robinson MS, Gizer I, Teicher MH, Cohen BM, Robertson D, Waldman ID, Blakely RD, Kim KS (2006) Proc Natl Acad Sci U S A 103(50): 19164-9
    › Primary publication · 17146058 (PubMed) · PMC1748193 (PubMed Central)
  100. The functional impact of SLC6 transporter genetic variation. Hahn MK, Blakely RD (2007) Annu Rev Pharmacol Toxicol : 401-41
    › Primary publication · 17067279 (PubMed)
  101. Amphetamine induces a calcium/calmodulin-dependent protein kinase II-dependent reduction in norepinephrine transporter surface expression linked to changes in syntaxin 1A/transporter complexes. Dipace C, Sung U, Binda F, Blakely RD, Galli A (2007) Mol Pharmacol 71(1): 230-9
    › Primary publication · 17032905 (PubMed)
  102. Deficits in acetylcholine homeostasis, receptors and behaviors in choline transporter heterozygous mice. Bazalakova MH, Wright J, Schneble EJ, McDonald MP, Heilman CJ, Levey AI, Blakely RD (2007) Genes Brain Behav 6(5): 411-24
    › Primary publication · 17010154 (PubMed)
  103. Na+, Cl-, and pH dependence of the human choline transporter (hCHT) in Xenopus oocytes: the proton inactivation hypothesis of hCHT in synaptic vesicles. Iwamoto H, Blakely RD, De Felice LJ (2006) J Neurosci 26(39): 9851-9
    › Primary publication · 17005849 (PubMed) · PMC6674471 (PubMed Central)
  104. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. Carneiro AM, Blakely RD (2006) J Biol Chem 281(34): 24769-80
    › Primary publication · 16803896 (PubMed) · PMC3875312 (PubMed Central)
  105. High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots. Tomlinson ID, Mason JN, Blakely RD, Rosenthal SJ (2006) Bioorg Med Chem Lett 16(17): 4664-7
    › Primary publication · 16784853 (PubMed)
  106. The Caenorhabditis elegans choline transporter CHO-1 sustains acetylcholine synthesis and motor function in an activity-dependent manner. Matthies DS, Fleming PA, Wilkes DM, Blakely RD (2006) J Neurosci 26(23): 6200-12
    › Primary publication · 16763028 (PubMed) · PMC6675188 (PubMed Central)
  107. Dopamine signaling architecture in Caenorhabditis elegans. McDonald PW, Jessen T, Field JR, Blakely RD (2006) Cell Mol Neurobiol 26(4-6): 593-618
    › Primary publication · 16724276 (PubMed)
  108. The high-affinity choline transporter: a critical protein for sustaining cholinergic signaling as revealed in studies of genetically altered mice. Bazalakova MH, Blakely RD (2006) Handb Exp Pharmacol (175): 525-44
    › Primary publication · 16722248 (PubMed)
  109. ADHD and the dopamine transporter: are there reasons to pay attention? Mazei-Robinson MS, Blakely RD (2006) Handb Exp Pharmacol (175): 373-415
    › Primary publication · 16722244 (PubMed)
  110. Getting the message across: a recent transporter structure shows the way. Henry LK, DeFelice LJ, Blakely RD (2006) Neuron 49(6): 791-6
    › Primary publication · 16543127 (PubMed)
  111. Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension. Keller NR, Diedrich A, Appalsamy M, Miller LC, Caron MG, McDonald MP, Shelton RC, Blakely RD, Robertson D (2006) Neuroscience 139(3): 931-46
    › Primary publication · 16515844 (PubMed)
  112. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Zhu CB, Blakely RD, Hewlett WA (2006) Neuropsychopharmacology 31(10): 2121-31
    › Primary publication · 16452991 (PubMed)
  113. Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. Miner LH, Jedema HP, Moore FW, Blakely RD, Grace AA, Sesack SR (2006) J Neurosci 26(5): 1571-8
    › Primary publication · 16452680 (PubMed) · PMC6675488 (PubMed Central)
  114. Overview: a rare opportunity or just one less reason to be depressed. Blakely RD (2005) Neuron 48(5): 701-2; author reply 705-6
    › Primary publication · 16337900 (PubMed)
  115. The N-terminus of the norepinephrine transporter regulates the magnitude and selectivity of the transporter-associated leak current. Binda F, Lute BJ, Dipace C, Blakely RD, Galli A (2006) Neuropharmacology 50(3): 354-61
    › Primary publication · 16289633 (PubMed)
  116. Serotonin transporter function is an early step in left-right patterning in chick and frog embryos. Fukumoto T, Blakely R, Levin M (2005) Dev Neurosci 27(6): 349-63
    › Primary publication · 16280633 (PubMed)
  117. Developmental expression of the high affinity choline transporter in cholinergic sympathetic neurons. Guidry G, Willison BD, Blakely RD, Landis SC, Habecker BA (2005) Auton Neurosci 123(1-2): 54-61
    › Primary publication · 16278103 (PubMed) · PMC1407245 (PubMed Central)
  118. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. Henry LK, Field JR, Adkins EM, Parnas ML, Vaughan RA, Zou MF, Newman AH, Blakely RD (2006) J Biol Chem 281(4): 2012-23
    › Primary publication · 16272152 (PubMed)
  119. Expression studies of naturally occurring human dopamine transporter variants identifies a novel state of transporter inactivation associated with Val382Ala. Mazei-Robison MS, Blakely RD (2005) Neuropharmacology 49(6): 737-49
    › Primary publication · 16212992 (PubMed)
  120. Inhibitors of the serotonin transporter protein (SERT): the design and synthesis of biotinylated derivatives of 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indoles. High-affinity serotonergic ligands for conjugation with quantum dots. Tomlinson ID, Mason JN, Blakely RD, Rosenthal SJ (2005) Bioorg Med Chem Lett 15(23): 5307-10
    › Primary publication · 16183285 (PubMed)
  121. Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD (2005) Neuropharmacology 49(6): 724-36
    › Primary publication · 16171832 (PubMed)
  122. Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Prasad HC, Zhu CB, McCauley JL, Samuvel DJ, Ramamoorthy S, Shelton RC, Hewlett WA, Sutcliffe JS, Blakely RD (2005) Proc Natl Acad Sci U S A 102(32): 11545-50
    › Primary publication · 16055563 (PubMed) · PMC1183547 (PubMed Central)
  123. Biogenic amine neurotransmitter transporters: just when you thought you knew them. Blakely RD, DeFelice LJ, Galli A (2005) Physiology (Bethesda) : 225-31
    › Primary publication · 16024510 (PubMed)
  124. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, Li C, Folstein SE, Blakely RD (2005) Am J Hum Genet 77(2): 265-79
    › Primary publication · 15995945 (PubMed) · PMC1224529 (PubMed Central)
  125. A genetic screen in Caenorhabditis elegans for dopamine neuron insensitivity to 6-hydroxydopamine identifies dopamine transporter mutants impacting transporter biosynthesis and trafficking. Nass R, Hahn MK, Jessen T, McDonald PW, Carvelli L, Blakely RD (2005) J Neurochem 94(3): 774-85
    › Primary publication · 15992384 (PubMed)
  126. Proteomic analysis of human norepinephrine transporter complexes reveals associations with protein phosphatase 2A anchoring subunit and 14-3-3 proteins. Sung U, Jennings JL, Link AJ, Blakely RD (2005) Biochem Biophys Res Commun 333(3): 671-8
    › Primary publication · 15963952 (PubMed)
  127. Peptide-conjugated quantum dots: imaging the angiotensin type 1 receptor in living cells. Tomlinson ID, Mason JN, Blakely RD, Rosenthal SJ (2005) Methods Mol Biol : 51-60
    › Primary publication · 15923674 (PubMed)
  128. Labeling cell-surface proteins via antibody quantum dot streptavidin conjugates. Mason JN, Tomlinson ID, Rosenthal SJ, Blakely RD (2005) Methods Mol Biol : 35-50
    › Primary publication · 15923673 (PubMed)
  129. Single nucleotide polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Hahn MK, Mazei-Robison MS, Blakely RD (2005) Mol Pharmacol 68(2): 457-66
    › Primary publication · 15894713 (PubMed)
  130. The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. Meredith EJ, Holder MJ, Chamba A, Challa A, Drake-Lee A, Bunce CM, Drayson MT, Pilkington G, Blakely RD, Dyer MJ, Barnes NM, Gordon J (2005) FASEB J 19(9): 1187-9
    › Primary publication · 15870169 (PubMed)
  131. Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation. Jayanthi LD, Samuvel DJ, Blakely RD, Ramamoorthy S (2005) Mol Pharmacol 67(6): 2077-87
    › Primary publication · 15774771 (PubMed)
  132. Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation. Mason JN, Farmer H, Tomlinson ID, Schwartz JW, Savchenko V, DeFelice LJ, Rosenthal SJ, Blakely RD (2005) J Neurosci Methods 143(1): 3-25
    › Primary publication · 15763132 (PubMed)
  133. Amphetamine induces dopamine efflux through a dopamine transporter channel. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A (2005) Proc Natl Acad Sci U S A 102(9): 3495-500
    › Primary publication · 15728379 (PubMed) · PMC549289 (PubMed Central)
  134. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. Zhu CB, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD (2005) J Biol Chem 280(16): 15649-58
    › Primary publication · 15728187 (PubMed)
  135. Norepinephrine modulates glutamatergic transmission in the bed nucleus of the stria terminalis. Egli RE, Kash TL, Choo K, Savchenko V, Matthews RT, Blakely RD, Winder DG (2005) Neuropsychopharmacology 30(4): 657-68
    › Primary publication · 15602500 (PubMed)
  136. Dopamine transporters depolarize neurons by a channel mechanism. Carvelli L, McDonald PW, Blakely RD, DeFelice LJ (2004) Proc Natl Acad Sci U S A 101(45): 16046-51
    › Primary publication · 15520385 (PubMed) · PMC528740 (PubMed Central)
  137. Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil. Zhu CB, Hewlett WA, Francis SH, Corbin JD, Blakely RD (2004) Eur J Pharmacol 504(1-2): 1-6
    › Primary publication · 15507214 (PubMed)
  138. Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice. Ferguson SM, Bazalakova M, Savchenko V, Tapia JC, Wright J, Blakely RD (2004) Proc Natl Acad Sci U S A 101(23): 8762-7
    › Primary publication · 15173594 (PubMed) · PMC423269 (PubMed Central)
  139. Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation. Zhu CB, Hewlett WA, Feoktistov I, Biaggioni I, Blakely RD (2004) Mol Pharmacol 65(6): 1462-74
    › Primary publication · 15155839 (PubMed)
  140. Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid-compulsive subset of autism. McCauley JL, Olson LM, Dowd M, Amin T, Steele A, Blakely RD, Folstein SE, Haines JL, Sutcliffe JS (2004) Am J Med Genet B Neuropsychiatr Genet 127B(1): 104-12
    › Primary publication · 15108191 (PubMed)
  141. Ultrastructural interactions between terminals expressing the norepinephrine transporter and dopamine neurons in the rat and monkey ventral tegmental area. Liprando LA, Miner LH, Blakely RD, Lewis DA, Sesack SR (2004) Synapse 52(4): 233-44
    › Primary publication · 15103690 (PubMed)
  142. Regulation of choline transporter surface expression and phosphorylation by protein kinase C and protein phosphatase 1/2A. Gates J, Ferguson SM, Blakely RD, Apparsundaram S (2004) J Pharmacol Exp Ther 310(2): 536-45
    › Primary publication · 15064333 (PubMed)
  143. Localization of cholinergic innervation in guinea pig heart by immunohistochemistry for high-affinity choline transporters. Hoover DB, Ganote CE, Ferguson SM, Blakely RD, Parsons RL (2004) Cardiovasc Res 62(1): 112-21
    › Primary publication · 15023558 (PubMed)
  144. The choline transporter resurfaces: new roles for synaptic vesicles? Ferguson SM, Blakely RD (2004) Mol Interv 4(1): 22-37
    › Primary publication · 14993474 (PubMed)
  145. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Proskocil BJ, Sekhon HS, Jia Y, Savchenko V, Blakely RD, Lindstrom J, Spindel ER (2004) Endocrinology 145(5): 2498-506
    › Primary publication · 14764638 (PubMed)
  146. Cell surface trafficking of the antidepressant-sensitive norepinephrine transporter revealed with an ectodomain antibody. Savchenko V, Sung U, Blakely RD (2003) Mol Cell Neurosci 24(4): 1131-50
    › Primary publication · 14697674 (PubMed)
  147. Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice. Volpicelli-Daley LA, Hrabovska A, Duysen EG, Ferguson SM, Blakely RD, Lockridge O, Levey AI (2003) Mol Pharmacol 64(6): 1309-16
    › Primary publication · 14645660 (PubMed)
  148. Vesicular localization and activity-dependent trafficking of presynaptic choline transporters. Ferguson SM, Savchenko V, Apparsundaram S, Zwick M, Wright J, Heilman CJ, Yi H, Levey AI, Blakely RD (2003) J Neurosci 23(30): 9697-709
    › Primary publication · 14585997 (PubMed) · PMC6740902 (PubMed Central)
  149. Ultrastructural localization of the norepinephrine transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to probable dopamine terminals. Miner LH, Schroeter S, Blakely RD, Sesack SR (2003) J Comp Neurol 466(4): 478-94
    › Primary publication · 14566944 (PubMed)
  150. Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I. Henry LK, Adkins EM, Han Q, Blakely RD (2003) J Biol Chem 278(39): 37052-63
    › Primary publication · 12869570 (PubMed)
  151. Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system. Kus L, Borys E, Ping Chu Y, Ferguson SM, Blakely RD, Emborg ME, Kordower JH, Levey AI, Mufson EJ (2003) J Comp Neurol 463(3): 341-57
    › Primary publication · 12820166 (PubMed)
  152. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. Lakso M, Vartiainen S, Moilanen AM, Sirviö J, Thomas JH, Nass R, Blakely RD, Wong G (2003) J Neurochem 86(1): 165-72
    › Primary publication · 12807436 (PubMed)
  153. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. Hahn MK, Robertson D, Blakely RD (2003) J Neurosci 23(11): 4470-8
    › Primary publication · 12805287 (PubMed) · PMC6740799 (PubMed Central)
  154. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. Sung U, Apparsundaram S, Galli A, Kahlig KM, Savchenko V, Schroeter S, Quick MW, Blakely RD (2003) J Neurosci 23(5): 1697-709
    › Primary publication · 12629174 (PubMed) · PMC6741950 (PubMed Central)
  155. Calcium-dependent inhibition of synaptosomal serotonin transport by the alpha 2-adrenoceptor agonist 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine (UK14304). Ansah TA, Ramamoorthy S, Montañez S, Daws LC, Blakely RD (2003) J Pharmacol Exp Ther 305(3): 956-65
    › Primary publication · 12626658 (PubMed)
  156. Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate. Schwartz JW, Blakely RD, DeFelice LJ (2003) J Biol Chem 278(11): 9768-77
    › Primary publication · 12499385 (PubMed)
  157. Genetic basis of clinical catecholamine disorders. Garland EM, Hahn MK, Ketch TP, Keller NR, Kim CH, Kim KS, Biaggioni I, Shannon JR, Blakely RD, Robertson D (2002) Ann N Y Acad Sci : 506-14
    › Primary publication · 12438171 (PubMed)
  158. The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Nass R, Blakely RD (2003) Annu Rev Pharmacol Toxicol : 521-44
    › Primary publication · 12415122 (PubMed)
  159. Developing novel treatments for mood disorders: accelerating discovery. Tamminga CA, Nemeroff CB, Blakely RD, Brady L, Carter CS, Davis KL, Dingledine R, Gorman JM, Grigoriadis DE, Henderson DC, B Innis RB, Killen J, Laughren TP, McDonald WM, M Murphy GM, Paul SM, Rudorfer MV, Sausville E, Schatzberg AF, Scolnick EM, Suppes T (2002) Biol Psychiatry 52(6): 589-609
    › Primary publication · 12361670 (PubMed)
  160. Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Hahn MK, Blakely RD (2002) Pharmacogenomics J 2(4): 217-35
    › Primary publication · 12196911 (PubMed)
  161. Determinants within the C-terminus of the human norepinephrine transporter dictate transporter trafficking, stability, and activity. Bauman PA, Blakely RD (2002) Arch Biochem Biophys 404(1): 80-91
    › Primary publication · 12127072 (PubMed)
  162. Targeting cell surface receptors with ligand-conjugated nanocrystals. Rosenthal SJ, Tomlinson I, Adkins EM, Schroeter S, Adams S, Swafford L, McBride J, Wang Y, DeFelice LJ, Blakely RD (2002) J Am Chem Soc 124(17): 4586-94
    › Primary publication · 11971705 (PubMed)
  163. 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Serafeim A, Grafton G, Chamba A, Gregory CD, Blakely RD, Bowery NG, Barnes NM, Gordon J (2002) Blood 99(7): 2545-53
    › Primary publication · 11895792 (PubMed)
  164. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Nass R, Hall DH, Miller DM, Blakely RD (2002) Proc Natl Acad Sci U S A 99(5): 3264-9
    › Primary publication · 11867711 (PubMed) · PMC122507 (PubMed Central)
  165. Molecular cloning and characterization of a murine hemicholinium-3-sensitive choline transporter. Apparsundaram S, Ferguson SM, Blakely RD (2001) Biochem Soc Trans 29(Pt 6): 711-6
    › Primary publication · 11709061 (PubMed)
  166. Physiological genomics of antidepressant targets: keeping the periphery in mind. Blakely RD (2001) J Neurosci 21(21): 8319-23
    › Primary publication · 11606618 (PubMed) · PMC6762804 (PubMed Central)
  167. Trafficking-dependent and -independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells. Apparsundaram S, Sung U, Price RD, Blakely RD (2001) J Pharmacol Exp Ther 299(2): 666-77
    › Primary publication · 11602680 (PubMed)
  168. Neurobiology. Dopamine's reversal of fortune. Blakely RD (2001) Science 293(5539): 2407-9
    › Primary publication · 11577225 (PubMed)
  169. Orthostatic intolerance: emerging genetic and environmental etiologies. Robertson D, Biaggioni I, Ertl AC, Robertson RM, Diedrich A, Blakely RD, Flattem N, Shannon JR (1999) J Gravit Physiol 6(1): P51-4
    › Primary publication · 11543025 (PubMed)
  170. Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Robertson D, Flattem N, Tellioglu T, Carson R, Garland E, Shannon JR, Jordan J, Jacob G, Blakely RD, Biaggioni I (2001) Ann N Y Acad Sci : 527-43
    › Primary publication · 11458707 (PubMed)
  171. The state of the serotonin transporter protein in the platelets of patients with somatoform [correction of somatiform] disorders. Belous AR, Ramamoorthy S, Blakely RD, Factor MI, Dupin AM, Katasonov AB, Lozier RH, Beniashvili AG, Morozova MA, Brusov OS (2001) Neurosci Behav Physiol 31(2): 185-9
    › Primary publication · 11392354 (PubMed)
  172. C. elegans: a novel pharmacogenetic model to study Parkinson's disease. Nass R, Miller DM, Blakely RD (2001) Parkinsonism Relat Disord 7(3): 185-191
    › Primary publication · 11331185 (PubMed)
  173. Autocrine regulation of norepinephrine transporter expression. Ren ZG, Pörzgen P, Zhang JM, Chen XR, Amara SG, Blakely RD, Sieber-Blum M (2001) Mol Cell Neurosci 17(3): 539-50
    › Primary publication · 11273648 (PubMed)
  174. Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Adkins EM, Barker EL, Blakely RD (2001) Mol Pharmacol 59(3): 514-23
    › Primary publication · 11179447 (PubMed)
  175. Ultrastructural localization of the serotonin transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to dopamine terminals. Miner LH, Schroeter S, Blakely RD, Sesack SR (2000) J Comp Neurol 427(2): 220-34
    › Primary publication · 11054690 (PubMed)
  176. Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. Apparsundaram S, Ferguson SM, George AL, Blakely RD (2000) Biochem Biophys Res Commun 276(3): 862-7
    › Primary publication · 11027560 (PubMed)
  177. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, Blakely RD (2000) J Neurosci 20(20): 7571-8
    › Primary publication · 11027216 (PubMed) · PMC6772869 (PubMed Central)
  178. SNARE-ing neurotransmitter transporters. Blakely RD, Sung U (2000) Nat Neurosci 3(10): 969-71
    › Primary publication · 11017164 (PubMed)
  179. Biogenic amine transporters: regulation in flux. Blakely RD, Bauman AL (2000) Curr Opin Neurobiol 10(3): 328-36
    › Primary publication · 10851182 (PubMed)
  180. Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD (2000) J Comp Neurol 420(2): 211-32
    › Primary publication · 10753308 (PubMed)
  181. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. Rakhshan F, Day TA, Blakely RD, Barker EL (2000) J Pharmacol Exp Ther 292(3): 960-7
    › Primary publication · 10688610 (PubMed)
  182. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D (2000) N Engl J Med 342(8): 541-9
    › Primary publication · 10684912 (PubMed)
  183. Modified structure of the human serotonin transporter promoter. Flattem NL, Blakely RD (2000) Mol Psychiatry 5(1): 110-5
    › Primary publication · 10673778 (PubMed)
  184. [The status of serotonin protein -- a serotonin transporter in thrombocytes in patients with somatoform disorders]. Belous AR, Rammamoorthy S, Blakely RD, Factor MI, Dupin AM, Katasonov AB, Lozier RKh, Beniashvili AG, Morozova MA, Brusov OS (1999) Zh Nevrol Psikhiatr Im S S Korsakova 99(11): 32-5
    › Primary publication · 10578533 (PubMed)
  185. Excess of serotonin (5-HT) alters the segregation of ispilateral and contralateral retinal projections in monoamine oxidase A knock-out mice: possible role of 5-HT uptake in retinal ganglion cells during development. Upton AL, Salichon N, Lebrand C, Ravary A, Blakely R, Seif I, Gaspar P (1999) J Neurosci 19(16): 7007-24
    › Primary publication · 10436056 (PubMed) · PMC6782873 (PubMed Central)
  186. [Decrease in the platelet level of 43 kDa immunoreactive fraction of serotonin transporting protein correlates with depressive symptoms in patients with somatoform disorders]. Belous AR, Ramamoothy S, Blakely RD, Faktor MI, Lozier RKh, Dupin AM, Bechiashvili AG, Morozova MA, Brusov OS (1999) Vopr Med Khim 45(3): 256-62
    › Primary publication · 10432563 (PubMed)
  187. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Ramamoorthy S, Blakely RD (1999) Science 285(5428): 763-6
    › Primary publication · 10427004 (PubMed)
  188. Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. Barker EL, Moore KR, Rakhshan F, Blakely RD (1999) J Neurosci 19(12): 4705-17
    › Primary publication · 10366604 (PubMed) · PMC6782662 (PubMed Central)
  189. Pharmacological profile of neuroleptics at human monoamine transporters. Tatsumi M, Jansen K, Blakely RD, Richelson E (1999) Eur J Pharmacol 368(2-3): 277-83
    › Primary publication · 10193665 (PubMed)
  190. Subcellular localization of chromogranins, calcium channels, amine carriers, and proteins of the exocytotic machinery in bovine splenic nerve. Leitner B, Lovisetti-Scamihorn P, Heilmann J, Striessnig J, Blakely RD, Eiden LE, Winkler H (1999) J Neurochem 72(3): 1110-6
    › Primary publication · 10037482 (PubMed)
  191. Transient developmental expression of monoamine transporters in the rodent forebrain. Lebrand C, Cases O, Wehrlé R, Blakely RD, Edwards RH, Gaspar P (1998) J Comp Neurol 401(4): 506-24
    › Primary publication · 9826275 (PubMed)
  192. Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins. Apparsundaram S, Schroeter S, Giovanetti E, Blakely RD (1998) J Pharmacol Exp Ther 287(2): 744-51
    › Primary publication · 9808705 (PubMed)
  193. Acute regulation of norepinephrine transport: I. protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. Apparsundaram S, Galli A, DeFelice LJ, Hartzell HC, Blakely RD (1998) J Pharmacol Exp Ther 287(2): 733-43
    › Primary publication · 9808704 (PubMed)
  194. Patch-clamp and amperometric recordings from norepinephrine transporters: channel activity and voltage-dependent uptake. Galli A, Blakely RD, DeFelice LJ (1998) Proc Natl Acad Sci U S A 95(22): 13260-5
    › Primary publication · 9789076 (PubMed) · PMC23775 (PubMed Central)
  195. Structural determinants of neurotransmitter transport using cross-species chimeras: studies on serotonin transporter. Barker EL, Blakely RD (1998) Methods Enzymol : 475-98
    › Primary publication · 9779469 (PubMed)
  196. Biosynthesis, N-glycosylation, and surface trafficking of biogenic amine transporter proteins. Ramamoorthy S, Melikian HE, Qian Y, Blakely RD (1998) Methods Enzymol : 347-70
    › Primary publication · 9779460 (PubMed)
  197. The Caenorhabditis elegans gene T23G5.5 encodes an antidepressant- and cocaine-sensitive dopamine transporter. Jayanthi LD, Apparsundaram S, Malone MD, Ward E, Miller DM, Eppler M, Blakely RD (1998) Mol Pharmacol 54(4): 601-9
    › Primary publication · 9765501 (PubMed)
  198. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Blakely RD, Ramamoorthy S, Schroeter S, Qian Y, Apparsundaram S, Galli A, DeFelice LJ (1998) Biol Psychiatry 44(3): 169-78
    › Primary publication · 9693389 (PubMed)
  199. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. Barker EL, Perlman MA, Adkins EM, Houlihan WJ, Pristupa ZB, Niznik HB, Blakely RD (1998) J Biol Chem 273(31): 19459-68
    › Primary publication · 9677366 (PubMed)
  200. Cloning and chromosomal mapping of the murine norepinephrine transporter. Fritz JD, Jayanthi LD, Thoreson MA, Blakely RD (1998) J Neurochem 70(6): 2241-51
    › Primary publication · 9603188 (PubMed)
  201. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Eur J Pharmacol 340(2-3): 249-58
    › Primary publication · 9537821 (PubMed)
  202. Down-regulation of the human norepinephrine transporter in intact 293-hNET cells exposed to desipramine. Zhu MY, Blakely RD, Apparsundaram S, Ordway GA (1998) J Neurochem 70(4): 1547-55
    › Primary publication · 9523572 (PubMed)
  203. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. Ramamoorthy S, Giovanetti E, Qian Y, Blakely RD (1998) J Biol Chem 273(4): 2458-66
    › Primary publication · 9442097 (PubMed)
  204. Structural diversity in the catecholamine transporter gene family: molecular cloning and characterization of an L-epinephrine transporter from bullfrog sympathetic ganglia. Blakely RD, Apparsundaram S (1998) Adv Pharmacol : 206-10
    › Primary publication · 9327880 (PubMed)
  205. Voltammetric approaches to kinetics and mechanism of the norepinephrine transporter. Justice JB, Danek KS, Kable JW, Barker EL, Blakely RD (1998) Adv Pharmacol : 191-4
    › Primary publication · 9327876 (PubMed)
  206. Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters. Eshleman AJ, Stewart E, Evenson AK, Mason JN, Blakely RD, Janowsky A, Neve KA (1997) J Neurochem 69(4): 1459-66
    › Primary publication · 9326274 (PubMed)
  207. Alternative splicing of the human serotonin transporter gene. Bradley CC, Blakely RD (1997) J Neurochem 69(4): 1356-67
    › Primary publication · 9326263 (PubMed)
  208. Polarized expression of the antidepressant-sensitive serotonin transporter in epinephrine-synthesizing chromaffin cells of the rat adrenal gland. Schroeter S, Levey AI, Blakely RD (1997) Mol Cell Neurosci 9(3): 170-84
    › Primary publication · 9245500 (PubMed)
  209. Serotonergic dorsal raphe nucleus projections to the cholinergic and noncholinergic neurons of the pedunculopontine tegmental region: a light and electron microscopic anterograde tracing and immunohistochemical study. Steininger TL, Wainer BH, Blakely RD, Rye DB (1997) J Comp Neurol 382(3): 302-22
    › Primary publication · 9183696 (PubMed)
  210. Drosophila serotonin transporters have voltage-dependent uptake coupled to a serotonin-gated ion channel. Galli A, Petersen CI, deBlaquiere M, Blakely RD, DeFelice LJ (1997) J Neurosci 17(10): 3401-11
    › Primary publication · 9133366 (PubMed) · PMC6573689 (PubMed Central)
  211. Molecular cloning and characterization of an L-epinephrine transporter from sympathetic ganglia of the bullfrog, Rana catesbiana. Apparsundaram S, Moore KR, Malone MD, Hartzell HC, Blakely RD (1997) J Neurosci 17(8): 2691-702
    › Primary publication · 9092590 (PubMed) · PMC6573121 (PubMed Central)
  212. Cloning and expression of the mouse serotonin transporter. Chang AS, Chang SM, Starnes DM, Schroeter S, Bauman AL, Blakely RD (1996) Brain Res Mol Brain Res 43(1-2): 185-92
    › Primary publication · 9037532 (PubMed)
  213. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice LJ, Blakely RD (1997) J Neurosci 17(1): 45-57
    › Primary publication · 8987735 (PubMed) · PMC6793697 (PubMed Central)
  214. Drug targets in the embryo. Studies on the cocaine- and antidepressant-sensitive serotonin transporter. Schroeter S, Blakely RD (1996) Ann N Y Acad Sci : 239-55
    › Primary publication · 8959038 (PubMed)
  215. Expression of the rat brain creatine transporter in situ and in transfected HeLa cells. Saltarelli MD, Bauman AL, Moore KR, Bradley CC, Blakely RD (1996) Dev Neurosci 18(5-6): 524-34
    › Primary publication · 8940628 (PubMed)
  216. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Barker EL, Blakely RD (1996) Mol Pharmacol 50(4): 957-65
    › Primary publication · 8863842 (PubMed)
  217. Expression and development of a functional plasmalemmal 5-hydroxytryptamine transporter by thyroid follicular cells. Tamir H, Hsiung SC, Liu KP, Blakely RD, Russo AF, Clark MS, Nunez EA, Gershon MD (1996) Endocrinology 137(10): 4475-86
    › Primary publication · 8828510 (PubMed)
  218. Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Burnette WB, Bailey MD, Kukoyi S, Blakely RD, Trowbridge CG, Justice JB (1996) Anal Chem 68(17): 2932-8
    › Primary publication · 8794928 (PubMed)
  219. Pore models for transporters? DeFelice LJ, Blakely RD (1996) Biophys J 70(2): 579-80
    › Primary publication · 8789077 (PubMed) · PMC1224960 (PubMed Central)
  220. Genetic linkage study of bipolar disorder and the serotonin transporter. Kelsoe JR, Remick RA, Sadovnick AD, Kristbjarnarson H, Flodman P, Spence MA, Morison M, Mroczkowski-Parker Z, Bergesch P, Rapaport MH, Mirow AL, Blakely RD, Helgason T, Egeland JA (1996) Am J Med Genet 67(2): 215-7
    › Primary publication · 8723051 (PubMed)
  221. Norepinephrine transporters have channel modes of conduction. Galli A, Blakely RD, DeFelice LJ (1996) Proc Natl Acad Sci U S A 93(16): 8671-6
    › Primary publication · 8710929 (PubMed) · PMC38731 (PubMed Central)
  222. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Melikian HE, Ramamoorthy S, Tate CG, Blakely RD (1996) Mol Pharmacol 50(2): 266-76
    › Primary publication · 8700133 (PubMed)
  223. Sodium-dependent GABA-induced currents in GAT1-transfected HeLa cells. Risso S, DeFelice LJ, Blakely RD (1996) J Physiol : 691-702
    › Primary publication · 8683468 (PubMed) · PMC1158707 (PubMed Central)
  224. Cell-specific sorting of biogenic amine transporters expressed in epithelial cells. Gu HH, Ahn J, Caplan MJ, Blakely RD, Levey AI, Rudnick G (1996) J Biol Chem 271(30): 18100-6
    › Primary publication · 8663573 (PubMed)
  225. A novel nonopioid action of enkephalins: competitive inhibition of the mammalian brain high affinity L-proline transporter. Fremeau RT, Velaz-Faircloth M, Miller JW, Henzi VA, Cohen SM, Nadler JV, Shafqat S, Blakely RD, Domin B (1996) Mol Pharmacol 49(6): 1033-41
    › Primary publication · 8649341 (PubMed)
  226. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD (1996) J Neurosci 16(7): 2352-64
    › Primary publication · 8601815 (PubMed) · PMC3327288 (PubMed Central)
  227. Tails of serotonin and norepinephrine transporters: deletions and chimeras retain function. Blakely RD, Moore KR, Qian Y (1993) Soc Gen Physiol Ser : 283-300
    › Primary publication · 8503051 (PubMed)
  228. Expression of a cocaine-sensitive norepinephrine transporter in the human placental syncytiotrophoblast. Ramamoorthy S, Prasad PD, Kulanthaivel P, Leibach FH, Blakely RD, Ganapathy V (1993) Biochemistry 32(5): 1346-53
    › Primary publication · 8448143 (PubMed)
  229. Regulation of the human serotonin transporter. Cholera toxin-induced stimulation of serotonin uptake in human placental choriocarcinoma cells is accompanied by increased serotonin transporter mRNA levels and serotonin transporter-specific ligand binding. Ramamoorthy S, Cool DR, Mahesh VB, Leibach FH, Melikian HE, Blakely RD, Ganapathy V (1993) J Biol Chem 268(29): 21626-31
    › Primary publication · 8408014 (PubMed)
  230. Cloning, expression, and localization of a chloride-facilitated, cocaine-sensitive serotonin transporter from Drosophila melanogaster. Demchyshyn LL, Pristupa ZB, Sugamori KS, Barker EL, Blakely RD, Wolfgang WJ, Forte MA, Niznik HB (1994) Proc Natl Acad Sci U S A 91(11): 5158-62
    › Primary publication · 8197200 (PubMed) · PMC43951 (PubMed Central)
  231. Expression of serotonin transporter messenger RNA in the human brain. Austin MC, Bradley CC, Mann JJ, Blakely RD (1994) J Neurochem 62(6): 2362-7
    › Primary publication · 8189241 (PubMed)
  232. Human norepinephrine transporter. Biosynthetic studies using a site-directed polyclonal antibody. Melikian HE, McDonald JK, Gu H, Rudnick G, Moore KR, Blakely RD (1994) J Biol Chem 269(16): 12290-7
    › Primary publication · 8163533 (PubMed)
  233. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. Pitt BR, Weng W, Steve AR, Blakely RD, Reynolds I, Davies P (1994) Am J Physiol 266(2 Pt 1): L178-86
    › Primary publication · 8141313 (PubMed)
  234. Functional characterization and chromosomal localization of a cloned taurine transporter from human placenta. Ramamoorthy S, Leibach FH, Mahesh VB, Han H, Yang-Feng T, Blakely RD, Ganapathy V (1994) Biochem J : 893-900
    › Primary publication · 8010975 (PubMed) · PMC1138249 (PubMed Central)
  235. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Barker EL, Kimmel HL, Blakely RD (1994) Mol Pharmacol 46(5): 799-807
    › Primary publication · 7969065 (PubMed)
  236. Restriction site-independent formation of chimeras from homologous neurotransmitter-transporter cDNAs. Moore KR, Blakely RD (1994) Biotechniques 17(1): 130-5, 137
    › Primary publication · 7946295 (PubMed)
  237. Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. Qian Y, Melikian HE, Rye DB, Levey AI, Blakely RD (1995) J Neurosci 15(2): 1261-74
    › Primary publication · 7869097 (PubMed) · PMC6577805 (PubMed Central)
  238. Molecular physiology of norepinephrine and serotonin transporters. Blakely RD, De Felice LJ, Hartzell HC (1994) J Exp Biol : 263-81
    › Primary publication · 7823027 (PubMed)
  239. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD (1993) Proc Natl Acad Sci U S A 90(6): 2542-6
    › Primary publication · 7681602 (PubMed) · PMC46124 (PubMed Central)
  240. The effect of N-linked glycosylation on activity of the Na(+)- and Cl(-)-dependent serotonin transporter expressed using recombinant baculovirus in insect cells. Tate CG, Blakely RD (1994) J Biol Chem 269(42): 26303-10
    › Primary publication · 7523405 (PubMed)
  241. Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD (1995) J Exp Biol 198(Pt 10): 2197-212
    › Primary publication · 7500004 (PubMed)
  242. Voltammetric recording from neostriatum of behaving rhesus monkey. Lindsay WS, Herndon JG, Blakely RD, Justice JB, Neill DB (1981) Brain Res 220(2): 391-6
    › Primary publication · 7284764 (PubMed)
  243. Increases in testosterone levels and in copulatory behavior of male rhesus monkeys following treatment with human chorionic gonadotrophin. Herndon JG, Allen WC, Blakely RD (1980) Horm Behav 14(4): 337-47
    › Primary publication · 7216185 (PubMed)
  244. Neuroleptics increase striatal catecholamine metabolites but not ascorbic acid in dialyzed perfusate. Blakely RD, Wages SA, Justice JB, Herndon JG, Neill DB (1984) Brain Res 308(1): 1-8
    › Primary publication · 6206916 (PubMed)
  245. A microcomputer controlled system for monitoring multiple voltammetric electrodes in vivo. Blakely RD, Duvarney RC (1983) Brain Res Bull 10(3): 315-20
    › Primary publication · 6133600 (PubMed)
  246. Specific alterations in the levels of N-acetyl-aspartyl-glutamate in the nervous system of the dystrophic mouse. Blakely RD, Ory-Lavollée L, Coyle JT (1987) Neurosci Lett 79(1-2): 223-8
    › Primary publication · 3670731 (PubMed)
  247. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. Robinson MB, Blakely RD, Couto R, Coyle JT (1987) J Biol Chem 262(30): 14498-506
    › Primary publication · 3667587 (PubMed)
  248. Neurochemical and immunocytochemical studies on the distribution of N-acetyl-aspartylglutamate and N-acetyl-aspartate in rat spinal cord and some peripheral nervous tissues. Ory-Lavollée L, Blakely RD, Coyle JT (1987) J Neurochem 48(3): 895-9
    › Primary publication · 3543223 (PubMed)
  249. Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl-L-glutamate in vitro. Robinson MB, Blakely RD, Coyle JT (1986) Eur J Pharmacol 130(3): 345-7
    › Primary publication · 3539626 (PubMed)
  250. Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Forloni G, Grzanna R, Blakely RD, Coyle JT (1987) Synapse 1(5): 455-60
    › Primary publication · 3505373 (PubMed)
  251. Quantitation of N-acetyl-aspartyl-glutamate in microdissected rat brain nuclei and peripheral tissues: findings with a novel liquid phase radioimmunoassay. Guarda AS, Robinson MB, Ory-Lavollée L, Forloni GL, Blakely RD, Coyle JT (1988) Brain Res 427(3): 223-31
    › Primary publication · 3401700 (PubMed)
  252. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity. Blakely RD, Robinson MB, Thompson RC, Coyle JT (1988) J Neurochem 50(4): 1200-9
    › Primary publication · 3346674 (PubMed)
  253. The neurobiology of N-acetylaspartylglutamate. Blakely RD, Coyle JT (1988) Int Rev Neurobiol : 39-100
    › Primary publication · 3061970 (PubMed)
  254. Expression of neurotransmitter transport from rat brain mRNA in Xenopus laevis oocytes. Blakely RD, Robinson MB, Amara SG (1988) Proc Natl Acad Sci U S A 85(24): 9846-50
    › Primary publication · 2904681 (PubMed) · PMC282878 (PubMed Central)
  255. Acidic peptides in brain: do they act at putative glutamatergic synapses? Coyle JT, Blakely R, Zaczek R, Koller KJ, Abreu M, Ory-Lavollée L, Fisher R, ffrench-Mullen JM, Carpenter DO (1986) Adv Exp Med Biol : 375-84
    › Primary publication · 2878566 (PubMed)
  256. Synaptosomal transport of radiolabel from N-acetyl-aspartyl-[3H]glutamate suggests a mechanism of inactivation of an excitatory neuropeptide. Blakely RD, Ory-Lavollée L, Thompson RC, Coyle JT (1986) J Neurochem 47(4): 1013-9
    › Primary publication · 2875126 (PubMed)
  257. A re-examination of the interaction of N-acetyl-L-aspartyl-L-glutamate with a subpopulation of rat brain membrane L-[3H]glutamate binding sites. Blakely RD, Robinson MB, Guarda AS, Coyle JT (1988) Eur J Pharmacol 151(3): 419-26
    › Primary publication · 2850921 (PubMed)
  258. Selective immunocytochemical staining of mitral cells in rat olfactory bulb with affinity purified antibodies against N-acetyl-aspartyl-glutamate. Blakely RD, Ory-Lavollée L, Grzanna R, Koller KJ, Coyle JT (1987) Brain Res 402(2): 373-8
    › Primary publication · 2435366 (PubMed)
  259. A device to rapidly core out tissue culture plates for autoradiographic visualization of cells transfected with cDNA libraries. Pacholczyk T, Blakely RD, Amara SG (1990) Biotechniques 9(5): 556, 558
    › Primary publication · 2268421 (PubMed)
  260. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Pacholczyk T, Blakely RD, Amara SG (1991) Nature 350(6316): 350-4
    › Primary publication · 2008212 (PubMed)
  261. Cloning and expression of a functional serotonin transporter from rat brain. Blakely RD, Berson HE, Fremeau RT, Caron MG, Peek MM, Prince HK, Bradley CC (1991) Nature 354(6348): 66-70
    › Primary publication · 1944572 (PubMed)
  262. Vaccinia-T7 RNA polymerase expression system: evaluation for the expression cloning of plasma membrane transporters. Blakely RD, Clark JA, Rudnick G, Amara SG (1991) Anal Biochem 194(2): 302-8
    › Primary publication · 1862934 (PubMed)
  263. Distinct, developmentally regulated brain mRNAs direct the synthesis of neurotransmitter transporters. Blakely RD, Clark JA, Pacholczyk T, Amara SG (1991) J Neurochem 56(3): 860-71
    › Primary publication · 1671586 (PubMed)
  264. Molecular biology of serotonin receptors and transporters. Blakely RD, Berson HE (1992) Clin Neuropharmacol : 351A-352A
    › Primary publication · 1498868 (PubMed)
  265. Molecular cloning and characterization of neurotransmitter transporters. Blakely RD (1992) NIDA Res Monogr : 66-83
    › Primary publication · 1362795 (PubMed)
  266. Molecular cloning and expression of a high affinity L-proline transporter expressed in putative glutamatergic pathways of rat brain. Fremeau RT, Caron MG, Blakely RD (1992) Neuron 8(5): 915-26
    › Primary publication · 1350201 (PubMed)